Moderna, Inc. (NASDAQ:MRNA - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2025 EPS estimates for Moderna in a research report issued on Wednesday, May 21st. Zacks Research analyst S. Ganoria now expects that the company will earn ($3.26) per share for the quarter, down from their prior estimate of ($3.10). The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. Zacks Research also issued estimates for Moderna's Q3 2025 earnings at ($2.09) EPS, Q4 2025 earnings at ($2.67) EPS, Q1 2026 earnings at ($2.26) EPS, Q2 2026 earnings at ($2.84) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($8.18) EPS, Q1 2027 earnings at ($1.88) EPS and FY2027 earnings at ($4.43) EPS.
Other equities research analysts have also issued reports about the stock. Royal Bank of Canada reduced their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research report on Thursday, May 22nd. Citigroup initiated coverage on shares of Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. UBS Group dropped their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Evercore ISI dropped their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $53.58.
Read Our Latest Analysis on Moderna
Moderna Stock Performance
Shares of MRNA stock traded down $0.96 during midday trading on Monday, hitting $25.97. 1,798,517 shares of the company were exchanged, compared to its average volume of 8,037,911. Moderna has a 52 week low of $23.15 and a 52 week high of $158.82. The firm's 50 day moving average price is $26.70 and its two-hundred day moving average price is $34.14. The firm has a market capitalization of $10.04 billion, a P/E ratio of -2.78 and a beta of 1.99.
Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's revenue was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($3.07) earnings per share.
Institutional Trading of Moderna
Several large investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB boosted its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares in the last quarter. S Bank Fund Management Ltd purchased a new position in Moderna in the 1st quarter worth about $25,000. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc bought a new stake in shares of Moderna during the 4th quarter valued at about $37,000. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the 4th quarter valued at about $41,000. Institutional investors own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
